It was reported that CRC harboring RAS mutations or mitogen‐activated protein kinase kinase (MEK) activation had less major histocompatibility complex‐I (MHC‐I) expression and lower CD8 T‐cell activation [46]. This evidence concerns the gene MAP2K7 and colorectal carcinoma.